The kidney type glutaminase (GLS1) is a biomarker for pathological diagnosis and prognosis of hepatocellular carcinoma: perspective multi-center trials

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-DDT-14005102

Enrollment

Unknown

Registered

2014-09-21

Start date

2015-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Gold Standard:

Index test:

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: the patients with liver lesions from 18 yrs. to 60 yrs, who don't undergo TACE before operation or liver biopsy

Exclusion criteria

Exclusion criteria: age beyond 18 yrs and 60 yrs or undergo TACE before trials

Design outcomes

Primary

Measure	Time frame
Sensitivity;Specificity;survival time;	—

Countries

China

Contacts

Public ContactDING Yi-tao

drdingyitao@sina.com.cn+86 025-83304616-66866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026